The White House is preparing to launch a direct-to-consumer website for Americans to buy prescription drugs at discounted prices negotiated by the federal government.
Senior administration officials told reporters on Tuesday that patients will be able to visit the site, TrumpRx.gov, in early 2026 to access direct-to-consumer prescription drugs that are priced according to President Donald Trump’s Most Favored Nation drug pricing program.
The announcement about TrumpRx came as part of a sweeping announcement of a deal between the administration and the pharmaceutical giant Pfizer, in which the drugmaker agreed to reduce the net price for prescriptions for U.S. customers, bringing them in parity with other developed countries.
Similar to Kayak or Expedia for booking travel plans, administration officials described TrumpRx as “a convening site where Americans can come and know that this is the place where they can go direct-to-consumer and access the lowest prices available.”
Administration officials said that they are still working on finalizing the details of the website, but that it will ultimately redirect patients to the websites of drug manufacturers where they will be able to directly purchase the medication.
It is not yet clear what products will be offered on the TrumpRx site, but the administration said that they will be based on the Most Favored Nation negotiated prices.
Trump during a press briefing in the Oval Office on Tuesday said that several pharmaceutical companies are in the process of negotiating with the administration.
“We’re going to show you some 1,000% drops in prices. There has never been anything like this in the history of medicine,” said Trump.
Increasing access to direct-to-consumer prescription plans was a pillar of Trump’s “most favored nation” executive order in May.
This summer, Trump set the deadline of Monday, Sept. 29, for pharmaceutical companies to begin implementing his Most Favored Nation platform.
In line with Trump’s deadline, the Pharmaceutical Research and Manufacturers of America, the industry’s chief lobbying group, announced on Monday that it will launch a similar platform to connect patients with manufacturer-direct purchasing programs.
PhRMA did not respond to the Washington Examiner’s request for comment on how its program, AmericanMedicines.com, will be different from TrumpRx.com.
TRUMP MAKES DEAL WITH PFIZER TO LOWER DRUG COSTS
Americans pay three times more for brand-name prescriptions than people in other developed countries, according to a White House fact sheet published in July. The U.S. also makes up 75% of global pharmaceutical profits despite having less than 5% of the world population.
